Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
JHBP/Gencor Biopharmaceutical (hereafter Gencor) is a China-based biotech company with a focus on oncology and autoimmune drugs with development programs for both China and the global market. The company has started book building to raise up to USD 371m to list in Hong Kong. In our previous note, we discussed that the company's main portfolio is BG491 (best-in-class CDK4/6), GB226 (PD-1), and three biosimilars (trastuzumab, infliximab, bevacizumab). The company has been slow in R&D for the tras...
JHBP/Gencor Biopharmaceutical (hereafter Gencor) is a China-based biotech company with a focus on oncology and autoimmune drugs with development programs for both China and the global market. In our previous note, we discussed that the company's main portfolio is BG491 (best-in-class CDK4/6), GB226 (PD-1), and three biosimilars (trastuzumab, infliximab, bevacizumab). While the CDK4/6 was a licensed-in product in 2020 and is potentially best-in-class oral CDK4/6 inhibitor for HR+/HER2- breast c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.